<ENAMEX TYPE="ORGANIZATION">Ciba-Geigy Ltd.</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Chiron Corp.</ENAMEX> began their previously announced $591 million, or $25.23-a-share, offer for the shares of <ENAMEX TYPE="ORGANIZATION">Connaught Biosciences Inc.</ENAMEX> that they don't already own.
As previously reported, the offer for the <ENAMEX TYPE="LOCATION">Toronto</ENAMEX>-based vaccine and pharmaceutical company is contingent upon the tender of at least 11 million <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> shares and the rejection by <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> shareholders of a rival stock-swap offer from <ENAMEX TYPE="ORGANIZATION">Institut Merieux S.A.</ENAMEX> of <ENAMEX TYPE="LOCATION">France</ENAMEX>, 50.3% controlled by <ENAMEX TYPE="ORGANIZATION">Rhone-Poulenc S.A.</ENAMEX>, <ENAMEX TYPE="LOCATION">France</ENAMEX>.
<ENAMEX TYPE="ORGANIZATION">Ciba-Geigy</ENAMEX>, the <ENAMEX TYPE="LOCATION">Basel</ENAMEX>, <ENAMEX TYPE="LOCATION">Switzerland</ENAMEX>-based pharmaceutical concern, and <ENAMEX TYPE="ORGANIZATION">Chiron</ENAMEX>, an <ENAMEX TYPE="LOCATION">Emeryville</ENAMEX>, <ENAMEX TYPE="LOCATION">Calif.</ENAMEX>, biotechnology concern, already own 8%, or 2,045,640 shares, of <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX>'s 25.5 million shares on a fully diluted basis. If the minimum 11 million shares are tendered, <ENAMEX TYPE="ORGANIZATION">Ciba-Geigy</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Chiron</ENAMEX>, through a unit created for the acquisition, would gain control of 51% of the Canadian firm.
<ENAMEX TYPE="ORGANIZATION">Ciba-Geigy</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Chiron</ENAMEX> said the offer will remain open through midnight <ENAMEX TYPE="LOCATION">Toronto</ENAMEX> time Oct. 17, unless it's withdrawn or extended.
